| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/21/2002 | EP1143935A3 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 02/21/2002 | DE10111224A1 Analoge der Ecstasy-Klasse sowie Verwendung derselben beim Nachweis von Verbindungen der Ecstasy-Klasse Analog ecstasy-class and use thereof in the detection of compounds of ecstasy-class |
| 02/21/2002 | CA2685447A1 Pharmaceutical composition |
| 02/21/2002 | CA2424160A1 Oral solid dose vaccine |
| 02/21/2002 | CA2420032A1 Oral delivery of peptide |
| 02/21/2002 | CA2419405A1 Steroid hormones as transfer agents |
| 02/21/2002 | CA2418716A1 Integrin binding motif containing peptides and methods of treating skeletal diseases |
| 02/21/2002 | CA2418490A1 Drug-containing solid dispersion having improved solubility |
| 02/21/2002 | CA2418380A1 Sutures and coatings made from therapeutic absorbable glass |
| 02/21/2002 | CA2417813A1 Improved solid pharmaceutical dosage formulation of hydrophobic drugs |
| 02/21/2002 | CA2416898A1 Method and composition for altering a b cell mediated pathology |
| 02/21/2002 | CA2385591A1 Composite material and process for increasing bioavailability and activity of a beneficial agent |
| 02/20/2002 | EP1180371A1 Agents promoting the formation of skin basement membrane, agents promoting the formation of artificial skin and process for producing artificial skin |
| 02/20/2002 | EP1180368A1 Freeze dried hgf preparations |
| 02/20/2002 | EP1180365A2 Aerosol formulations of peptides and proteins |
| 02/20/2002 | EP1180364A1 Steroid hormones as transfer agents |
| 02/20/2002 | EP1180355A1 Glass ionomer-based fluoride applying material |
| 02/20/2002 | EP1180239A2 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |
| 02/20/2002 | EP1180150A2 Nucleic acid immunization |
| 02/20/2002 | EP1180123A1 Immunoconjugates having high binding affinity |
| 02/20/2002 | EP1180116A2 Fap-activated anti-tumor compounds |
| 02/20/2002 | EP1180102A1 Mutual prodrugs of amlodipine and atorvastatin |
| 02/20/2002 | EP1180097A1 Mutual salt of amlodipine and atorvastatin |
| 02/20/2002 | EP1180062A1 Method for producing morphologically uniform micro and nanoparticles using micromixers |
| 02/20/2002 | EP1180042A1 Model membrane systems |
| 02/20/2002 | EP1180033A2 Lamivudine containing pharmaceutical formulation |
| 02/20/2002 | EP1180020A2 Porous drug matrices and methods of manufacture thereof |
| 02/20/2002 | EP1180017A1 Preparation for the application of anti-infective and/or anti-inflammatory agents |
| 02/20/2002 | EP1180015A1 Generation of therapeutic microfoam |
| 02/20/2002 | EP1180014A2 Injectable anesthetic formulation |
| 02/20/2002 | EP1180012A1 Niacinamide compositions with reduced tack |
| 02/20/2002 | EP1028707B1 Sustained release ophthalmic compositions containing water soluble medicaments |
| 02/20/2002 | EP0934079B1 Pharmaceutical composition containing lornoxicam and a disodic salt of edta |
| 02/20/2002 | EP0893994B1 Diclofenac/gamma-cyclodextrin inclusion compounds |
| 02/20/2002 | EP0730447B1 Fatty acid delivery system |
| 02/20/2002 | EP0728215B1 METHOD OF BINDING MATERIAL TO THE Beta-AMYLOID PEPTIDE |
| 02/20/2002 | CN1336940A Biodegradable and thermosensitive polyphosphazenes and their prepn. method |
| 02/20/2002 | CN1336828A Composition and method for the enhancement of the efficacy of drugs |
| 02/20/2002 | CN1336827A Medicinal compositions for oral use |
| 02/20/2002 | CN1336823A Compositions having improved delivery of actives |
| 02/20/2002 | CN1336822A Compositions having improved stability |
| 02/20/2002 | CN1336820A Method for producing film-type dosage forms |
| 02/20/2002 | CN1336819A Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| 02/20/2002 | CN1079234C Trip;henyl diamidine enteric coated table as vermifuge |
| 02/19/2002 | US6348568 Hybrid polypeptides with enhanced pharmacokinetic properties |
| 02/19/2002 | US6348508 Method for treating dry eye |
| 02/19/2002 | US6348501 Lotions with carriers, capsaicin, lavender oil, myristal myristate |
| 02/19/2002 | US6348491 Triglyceride, emulsifiers, drugs, water and solutions |
| 02/19/2002 | US6348350 A nucleic acid that codes a mammalian native ligand tyrosine kinase containing an immunoglobulin and an epidermal growth factor domain; that induces vasculariation; diagnosis and therapy for promoting or inhibiting neovascularization |
| 02/19/2002 | US6348264 Process for producing low de starch hydrolysates by nanofiltration fractionation, products obtained thereby, and use of such products |
| 02/19/2002 | US6348229 Food comprising thixotropic composition of unsaturated fat and process for manufacture thereof |
| 02/19/2002 | US6348214 Materials and methods for making improved liposome compositions |
| 02/19/2002 | US6348211 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| 02/19/2002 | US6348209 Inhalation comprising an effective amount of a vesicant and a pharmeceutically acceptable carrier, wherein the vesicant does not exhibit substantial toxicity while treating a patient for neoplasm |
| 02/19/2002 | US6348207 Exposing biologically active agent to complexing perturbant to reversibly transform biologically active agent to intermediate state and form orally deliverable supramolecular complex, orally administering complex to subject |
| 02/19/2002 | US6348203 Antimicrobial metronidazole and tinidizole in suspension with a polysaccharide, a water miscible alkylene glycolsolvent and water; hydrogel that is less prone to irritate inflamed or sensitive skin |
| 02/19/2002 | US6348194 Tumor specific internalizing antigens and methods for targeting therapeutic agents |
| 02/19/2002 | US6348186 Preparation of further diagnostic agents |
| 02/19/2002 | US6348185 Functional moiety linking peptide to diagnostic or pharmaceutically active substance and which confers target cell specificity to said compound; radiotherapy and drug delivery; conjugate coordination and covalent complexes; |
| 02/19/2002 | US6348184 Contacting inert support material with aqueous solution of radioactive salt of phosphoric acid, whereby radioactive salt is adsorbed on support material and converting salt to corresponding radioactive salt of pyrophosphoric acid |
| 02/19/2002 | US6348090 Film coatings and film coating compositions based on dextrin |
| 02/19/2002 | CA2074730C Immobilized polyethylene oxide star molecules for bioapplications |
| 02/14/2002 | WO2002012369A1 Lactic acid polymer and process for producing the same |
| 02/14/2002 | WO2002012266A1 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 02/14/2002 | WO2002012265A1 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT |
| 02/14/2002 | WO2002012258A1 New immunoeffector compounds |
| 02/14/2002 | WO2002012241A1 Compounds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated diseases or dysfunction |
| 02/14/2002 | WO2002011803A1 Electro-powder |
| 02/14/2002 | WO2002011784A2 Pharmaceutical carriers and compositions for transdermal drug delivery |
| 02/14/2002 | WO2002011772A2 Radiolabelled metal transport proteins as imaging agents |
| 02/14/2002 | WO2002011770A1 Compositions for preventing urinary calculus |
| 02/14/2002 | WO2002011768A1 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| 02/14/2002 | WO2002011758A1 Vaccine against the influenza virus and method for producing said virus vaccine |
| 02/14/2002 | WO2002011753A1 Protein injection preparations |
| 02/14/2002 | WO2002011743A2 Treatment of prostate cancer |
| 02/14/2002 | WO2002011740A2 'slow release' pharmaceutical compositions comprising lithium carbonate |
| 02/14/2002 | WO2002011733A1 Pharmaceutical composition comprising condensed indole compound |
| 02/14/2002 | WO2002011728A2 Pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
| 02/14/2002 | WO2002011727A1 Stable pergolide mesylate and process for making same |
| 02/14/2002 | WO2002011726A1 Highly absorbable solid preparation |
| 02/14/2002 | WO2002011716A2 Liquid formulation of metformin |
| 02/14/2002 | WO2002011710A2 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 02/14/2002 | WO2002011702A2 Hydrogel-driven drug dosage form |
| 02/14/2002 | WO2002011700A1 Analgesic, anti-inflammatory and skeletal muscle relaxant compositions |
| 02/14/2002 | WO2002011698A1 Novel compositions of minoxidil |
| 02/14/2002 | WO2002011697A1 A method of preparing a pharmaceutical composition |
| 02/14/2002 | WO2002011695A2 Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation |
| 02/14/2002 | WO2002011694A2 Compositions and dosage forms for application in the oral cavity in the treatment of mykoses |
| 02/14/2002 | WO2002011683A1 Topical gel delivery system |
| 02/14/2002 | WO2002011669A2 Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof |
| 02/14/2002 | WO2002011666A2 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 02/14/2002 | WO2002011564A2 Supplement for type 2 diabetes or lipodystrophy |
| 02/14/2002 | WO2002011540A1 Rotavirus vaccine formulations |
| 02/14/2002 | WO2002005844A8 Protein complex serving as a vehicle for orally administerable medicaments |
| 02/14/2002 | WO2001081415A9 Parathyroid hormone and parathyroid hormone-related protein antagonists |
| 02/14/2002 | WO2001076633A3 Targeted transfection of cells using a biotinylated dendrimer |
| 02/14/2002 | WO2001076531A3 Bile acid containing prodrugs with enhanced bioavailability |
| 02/14/2002 | WO2001072264A3 Pro-liposomal encapsulated preparations (iv) |
| 02/14/2002 | WO2001066115A3 Acetylsalicylic acid solutions |
| 02/14/2002 | WO2001062283A3 Mucosal adjuvant formulation |